PGD

It is now possible to evaluate the chromosomal and genetic features of embryonic cells in their very first stages. CER offers patients the most comprehensive version of this study in conjunction with the well-known New Jersey hospital St. Barnabas (USA).

 

Unlike other fertility centers in Argentina, CER does the PGD on 9 or 12 chromosomes –and in some cases, on 24 chromosomes- instead of only 3 or 5 chromosomes. In this way, an embryo can be implanted with greater safety and reliability; embryos can be chosen so as to avoid those carrying hereditary illnesses or those that are abnormal in terms of quantity or molecular features and which could lead to disabilities. In other words, CER gives its patients the most trustworthy scientific guarantee currently available.

 

The PGD study done at our center reduces the frequency of conceptions with chromosomal anomalies by 400%. In addition, it increases the rate of embryo implantation and reduces miscarriages from 23 to 9%.

 

Doing a biopsy on one or two embryonic cells will not affect the fetus’s development. The biopsy of the blastocyst can be compared to the cellular loss suffered by certain embryos after freezing. All the embryonic cells are totipotent until at least the fourth day of development. “Totipotent” means that the cell has “full potential.” The procedure momentarily detains cell division; afterwards, the embryo reaches the same number of cells it previously had and continues to develop normally.

 

Since this procedure’s reliability rate is 90%, we recommend that all of our patients do a second chromosomal and genetic study when the embryo is successfully implanted in the uterus in order to confirm the data from the PGD.